Shares of Instacart parent Maplebear (CART) will soon be included in the S&P MidCap 400 index. Instacart stock climbed Wednesday on the news.
The S&P Dow Jones Indices said in a news that shares of the grocery delivery company will be added to the index effective Jan. 14, in a news release late Tuesday. Instacart stock will replace medical technology company Enovis Corp. (ENOV) in the index, with Enovis stock moving down to the S&P SmallCap 600. Enovis is replacing Arch Resources (ARCH), a coal supplier that is being acquired by CONSOL Energy (CEIX).
↑ XOn the stock market today, Instacart stock is up 4.7% at 44.92 in recent premarket action. The early action indicates Instacart stock will retake its 50-day moving average after dipping below the support level in trading Tuesday.
Maplebear completed an initial public offering in September 2023 and Instacart stock has gained 42% from the company's first-day closing price. That included, however, a more than 80% gain in 2024.
In its most recent third quarter earnings report from November, Instacart beat expectations with earnings of 42 cents per share and sales growth of 12% to $852 million. But Instacart stock fell following the report on concerns about the company's Q4 sales outlook.
The stock has since formed a consolidation pattern, with an early November all-time high of 50.01 representing the buy point, according to MarketSurge.
Investors could use Monday's high of 45.49 as an early entry.
Instacart stock has an IBD Composite Rating of 76 out of a best-possible 99, according to IBD Stock Checkup. The score combines five separate proprietary ratings into one rating. The best growth stocks have a Composite Rating of 90 or better.
Meanwhile, CART stock has an IBD Relative Strength Rating of 87 out of 99. The RS Rating means that Instacart has outperformed 87% of all stocks in IBD's database over the past year.
YOU MAY ALSO LIKE:
Uber Stock Gains On $1.5 Billion Accelerated Stock Buyback. CFO Says Uber 'Undervalued.'
IBD Live: Learn And Analyze Growth Stocks With The Pros
Get Timely Buy & Sell Alerts With IBD Leaderboard
Top Growth Stocks To Buy And Watch
Learn How To Time The Market With IBD's ETF Market Strategy
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。